



# Hester Pharmaceuticals Limited

Regd. Off.: Village: Merda-Adraj • Tal: Kadi • Dist: Mehsana • Gujarat - 382 721 • India



## Unaudited Financial Results for the quarter ended on 31st December, 2007

Rs.in Lacs						
Sr.No.	Particulars	Quarter ended on	Quarter ended on	Nine Months ended On	Nine Months ended on	Year ended on
		31/12/2007	31/12/2006	31/12/2007	31/12/2006	31/03/2007
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Manufacturing Sales	873.48	528.73	2586.42	1568.98	2160.11
	Trading Sales	10.93	1.67	31.19	16.87	22.68
	<b>Net Income from Sales</b>	<b>884.41</b>	<b>530.40</b>	<b>2617.61</b>	<b>1585.85</b>	<b>2182.79</b>
2	Other Income	12.54	1.78	27.09	7.45	26.32
3	<b>Total Income</b>	<b>896.95</b>	<b>532.18</b>	<b>2644.70</b>	<b>1593.30</b>	<b>2209.11</b>
4	<b>Total Expenses</b>	<b>519.52</b>	<b>329.91</b>	<b>1486.97</b>	<b>970.51</b>	<b>1345.73</b>
	(a) (Increase)/decrease in Stock in trade	-40.10	18.91	-71.77	-29.10	-225.42
	(b) Trading Purchase	0.00	19.25	38.74	153.93	30.46
	(c) Consumption of Raw material	153.76	101.76	439.43	254.35	709.37
	(d) Manufacturing Expenses	96.46	39.60	266.01	155.12	222.10
	(e) Staff Cost	90.75	52.85	212.63	138.93	196.40
	(f) Depreciation.	96.36	9.54	270.16	28.17	44.09
	(g) Selling, General & Admn.Expenses	122.29	88.00	331.77	269.11	368.73
5	Interest	63.03	14.76	204.39	39.27	69.77
6	<b>Profit Before Tax</b>	<b>314.40</b>	<b>187.51</b>	<b>953.34</b>	<b>583.52</b>	<b>793.61</b>
7	Provision for taxation	109.20	63.75	320.00	202.05	278.48
8	<b>Net Profit</b>	<b>205.20</b>	<b>123.76</b>	<b>633.34</b>	<b>381.47</b>	<b>515.13</b>
9	Paid-up equity share capital	519.12	519.12	519.12	519.12	519.12
10	Reserves & Surplus					2397.05
11	<b>EPS (Rs.) (not annualised)</b>	<b>3.95</b>	<b>2.38</b>	<b>12.20</b>	<b>7.35</b>	<b>11.14</b>
12	Aggregate of Non Promoters					
	Number of Share	2952124	2971424	2952124	2971424	2969424
	%of Shareholding	56.87	57.24	56.87	57.24	57.20

- Note:**
1. The Board of Directors have approved the aforesaid working result at their meeting held on 21st January, 2008, after reviewed by the Audit Committee of the Company.
  2. The Limited Review Report for the quarter as required under clause 41 of the listing agreement with Stock Exchange has been carried out by the Statutory Auditor.
  3. Segment wise reporting as defined in Accounting Standard (AS-17) is not applicable, since the entire operation of the Company relates to only one segment i.e. "Poultry Vaccines".
  4. No investor complaints were pending at the beginning and at the end of the quarter. During the quarter, three complaints were received and resolved.
  5. Provision for taxation includes Current Tax, FBT and Deferred Tax Liability for the quarter as per Accounting Standard (AS-22).

By Order of the Board

Place : Ahmedabad

**Rajiv Gandhi**  
CEO & Managing  
Director

Date : 21st January, 2008